In breast cancer, p-mTOR expression is predominantly detected in the cytoplasm and is significantly associated with short RFS, but does not correlate with any clinicopathological factors, including stage, histological grade, and lymph node involvement (Zhou et al, 2004). Here, MTOR is linked to breast carcinoma.